Approval for FOSRENOL , which controls phosphate amounts in renal dialysis patients Sweden approves innovative treatment to reduce phosphate risk in sufferers with end stage renal failure; right now FOSRENOL to enter EU mutual reputation procedure Sweden’s MPA provides today granted the first regulatory approval in the world for FOSRENOL , a non-calcium, non-aluminium phosphate binding medicine developed to control phosphate levels in renal dialysis patients. Sweden shall now become the Reference Member State in the EU Mutual Acknowledgement Procedure for FOSRENOL, and this is the first rung on the ladder in securing marketing authorization throughout European countries ?inflammation of the passageways .
Aquapharm Biodiscovery signs analysis agreement with AMRI Aquapharm Biodiscovery, a leading marine biotechnology company, announced today it offers signed a research agreement with Albany Molecular Research to recognize novel drug-like substances and scaffolds with anti-microbial and anti-inflammatory activity from Aquapharm’s marine natural basic products library produced from its extensive collection of marine micro-organisms. Aquapharm retains all privileges to compounds resulting from the collaboration. Related StoriesData displays romosozumab much better than teriparatide in raising bone power in postmenopausal womenRXi Pharmaceuticals starts Phase 1/2 medical trial in ophthalmologyUsing smartphone to identify diabetes marker in salivaThe collaboration represents a significant step-forward for Aquapharm in realising the potential of its unique marine assets and expertise in the Pharmaceutical sector.